Accrufer
Payments companies reported to CMS as associated with Accrufer. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Accrufer, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Accrufer
These are the largest totals companies reported as associated with Accrufer. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| David Adler | Loxahatchee, FL | Obstetrics & Gynecology | $12,544.68 |
| Malcolm Munro | Los Angeles, CA | Obstetrics & Gynecology | $6,921.91 |
| Rochelle Nazarian | Danvers, MA | Family | $6,557.41 |
| Ilya Blokh | Brooklyn, NY | Hematology & Oncology | $6,506.46 |
| Enrico Novelli | Pittsburgh, PA | Internal Medicine | $6,293.58 |
| Girish Kunapareddy | Terre Haute, IN | Internal Medicine | $4,984.89 |
| Faisal Musa | Dearborn, MI | Hematology & Oncology | $4,877.72 |
| Shyam Khanwani | Fayetteville, GA | Hematology & Oncology | $4,830.60 |
| Jewraj Maheshwari | Owensboro, KY | Medical Oncology | $4,637.23 |
| Lee Shulman | Chicago, IL | Obstetrics & Gynecology | $4,519.57 |
Prescribed Accrufer?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.